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The relationship between Campylobacter pylori
histologic gastritis, and dyspeptic symptoms is becom-
ing gradually clearer, hut there is still a lack of knowl-
edge of the natural history of treated or untreated
gastritis. We examined serial biopsies from the gastric
fundus, body, and antrum, and from the duodenum in
16 dyspeptic patients. Patients with concomitant peptic
ulcers, alcoholism, or nonsteroidal anti-inflammatory
drug use were excluded. CP was present in the hiopsies
of 50% of patients at presentation. When CP was
present, the antrum was always infected, and often had
the highest density of organisms. In the duodenum, CP
was found only in areas of gastric metaplasia. The
presence of CP was highly correlated with gastritis
activity (neutrophilic infiltrate).
A 4-yr follow-up study of symptoms, endoscopic ap-
pearance, and histologic findings including the presence
of CP was performed in 10 of the original 16 patients.
After 4 yr, both the severity and frequency of epigastric
pain remained the same in seven patients, worsened in
one, and improved in two. All patients who had CP at
initial presentation retained the organism (5/10),
whereas none of the previously noninfected patients
acquired the infection (5/10). Both CP-positive and
-negative patients were treated for 3 wk with 524 mg
bismuth subsalicylate qid, and for the first 2 of 3 wk
with 250 mg metronidazole qid. One patient who was
CP positive was lost to follow-up. In three of the re-
maining four patients on this regimen, the organism
was eradicated. Of the nine patients who completed the
treatment program, two had no change in symptoms
and seven improved. CP was present in three of seven
with improved symptoms and in one of two with no
change in symptoms. After treatment, the only change
in histology was the disappearance of activity in the
CP-positive patients who lost the organism. In conclu-
sion, CP was present in 50% of dyspeptic patients with
endoscopic evidence of at least one erosion. Both the
symptoms and CP persisted for 4 yr. Dyspeptic symp-
toms improved after bismuth subsalicylate/metronida-
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zole therapy, regardless of the presence or ahsence of
CP, although the regimen did succeed in eradicating the
organism in three of the four CP-positive patients who
completed the study.
INTRODUCTION
The relationship between endoscopically diagnosed
gastroduodenitis, histologic gastritis, and dyspeptic
symptoms remains unclear. It has been demonstrated
that the endoscopic diagnosis of gastritis often correlates
poorly with histologic inflammation (1.2). In addition,
there has been controversy as to whether treatment of
dyspeptic symptoms by reducing gastrie acid in the
absence of documented ulcer disease is of benefit (3,
4). This lack of benefit may be due to the heterogeneous
nature ofthe population labeled as non-ulcer dyspepsia.
One subgroup of patients who might respond to specific
therapy are those with Campylobacter pylori (CP)-
associated gastritis. Previous studies have demonstrated
a 40-70% incidence of CP and gastritis in non-ulcer
dyspeptic patients (5-7). To examine the relationship
between symptoms, CP, and gastritis, we studied 16
patients with the endoscopic diagnosis of erosive gas-
troduodenitis. The presence of gastritis and CP infec-
tion was determined by histologic examination of biop-
sies in all patients. Ten ofthe original 16 patients had
a 4-yr follow-up examination for persistence of symp-
toms, endoscopic and histologic changes, and CP infec-
tion. After this 4-yr follow-up evaluation, these 10
patients were treated with bismuth subsalicylate and
metronidazole and then reassessed.
METHODS
Of patients who underwent routine esophagogastro-
duodenoscopy for persistent dyspeptic symptoms, 16
were chosen for this study on the basis ofthe endoscopic
diagnosis of erosive gastroduodenitis defined as at least
one erosion in either the stomach or duodenum. Dys-
pepsia was defined as chronic or recurrent epigastric
pain or nausea. Erosions were defined as breaks in
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mucosa (<5 mm) with no appreciable depth. Patients
were excluded if they had used aspirin or nonsteroidal
anti-inflammatory drugs (NSAIDs) within 48 h of en-
doscopy, had a history of alcoholism, prior gastric
surgery, or concomitant ulcer disease, or had used
antacids, H^-blockers, or sucralfate within 4 days of
entry. The age range ofthe 16 patients was 18-77 yr,
with a mean age of 48.6 yr for the patients with CP
infection and a mean age of 44.1 yr for those without
histological evidence of CP infection. Symptom ques-
tionnaires at each patient visit graded daytime and
nocturnal epigastric pain, nausea, anorexia, and bloat-
ing on a 0-4 scale of severity (0 = none, I = mild, 2 =
moderate- 3 = severe, and 4 = unbearable) and a 0-4
scale of frequency (0 = none, I = few or pain on 1-2
days/wk, 2 = several or pain on 3-4 days/wk. 3 =
many or pain on 5-6 days/wk, and 4 = continual).
At endoscopy, biopsies were taken from the gastric
fundus, body, and antrum, as well as the duodenum.
Biopsies were stained with both Warthin-Starrv' and
hemotoxylin and eosin. They were graded on the sever-
ity of plasma cell infiltration (chronic inflammation)
with 0 = normal, 1 = focal superficial involving the pit
compartment, 2 = diffuse superficial, 3 = midmucosal,
extending into the middle of the mucosa and 4 =
transmucosal, presence of polymorphonuclear cells in
the pit epithelium (none = —, few = -I-, many = ++),
and presence of CP (— = absent, + = present) (Figs. 1
and 2). Four years later, we attempted to contact these
16 patients for follow-up examination. Ten ofthe orig-
inal 16 patients returned for endoscopy with four-site
biopsies and symptom assessment. All 10 patients then
were treated for 3 wk with bismuth subsaHcylate tablets,
524 mg qid, and for the first 2 of the 3 wk with
f
FIG. 1. Antral mucosa before treatment in a patient with grade 3
chronic inflammation and CP. Note the neutrophils in the epithelium
of the necks (activity). The dense cellularity in the lamina propria
consists mostly of plasma cells (bematoxylin and eosin, xl32).
FIG. 2. Antral mucosa from the same patient in Figure I after
bismuth subsalicylatc and metronidazole treatment with grade 2
chronic inflammation and no activity (hematoxylin and eosin, x 132).
metronidazole 250 mg qid. Endoscopy with biopsies
was repeated in all patients at the study conclusion.
Symptom questionnaires identical lo that given 4 yr
previously were filled out before and after treatment.
An improvement or worsening in pain score was de-
fined as a change of 2 or more points. Due to the
previously reported high CP relapse rate within the first
month post-treatment, we restudied the patients who
initially cleared the organism immediately after treat-
ment, 6-8 months later, to look for relapses of infection.
This project was approved by the human use committee
at the University of Michigan in June 1987.
RESULTS
CP were found in eight ofthe original 16 patients.
Neither the presence of symptoms considered typical
of dyspepsia or the severity of symptoms were predictive
of CP infection. At 4 yr of follow-up, five ofthe original
eight CP-positive patients and five ofthe original eight
CP-negative patients were restudied. After four yr, CP
persisted in all five CP-pjositive patients, and none of
the five CP-negative patients newly acquired the orga-
nism. The treatment regimen successfully eradicated
the organism in three of four CP-positive patients; one
patient was lost to follow-up. The one patient who
failed to clear had poor compHance with the bismuth
subsaHcylate. Follow-up biopsies from the three pa-
tients who cleared the organism at 6-8 months after
completion of treatment showed continued absence of
CP infection in two, with evidence for relapse in one.
After 4 yr. both the severity and frequency of epigas-
tric pain remained the same in seven of 10 patients,
worsened in one of 10, and improved in two of 10.
After the metronidazole and bismuth subsaHcylate
treatment trial, two of nine had no change in symptoms,
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whereas seven of nine improved. Symptom improve-
ment in the nine patients did not correlate with CP
presence or eradication (Fig. 3).
The endoscopic appearance of the mucosa improved
in the majority of patients after 4 yr; only one of 10
patients had persistent erosions and three of 10 had
erythema. No patient developed interval ulcer disease.
Following the treatment regimen, there was no change
in the endoscopic appearance. The histologic findings
of chronic inflammation, presence of activity, and pres-
ence of CP was examined in 152 specimen sites. CP
infection was never found on normal mucosa. In the
duodenum, it involved only areas of gastric metaplasia.
In our CP-positive patients, the antrum was always
infected, and often had the highest density of organisms
(Table I). The presence ofCP correlated perfectly with
activity in gastritis in the antrum, but the correlation
was somewhat less perfect in the body, and especially
in the fundus. The severity of the histologic chronic
inflammation was unchanged over 4 yr. After the 3-wk
treatment period, the only change in histology was
disappearance of PMNs in the CP-positive patients. At
TABLE 1
Hisiotogic Scores in the Anlrum*
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FIG. 3. The pain score is the sum of 4 scores for both severity and
frequency of both daytime and nighttime pain (0-4 each). This is
plotted against time for patients witli and without CP infection at the
initial evaluation.
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* Chronic inflammatory infiltrate is scored 0-4 and activity is
scored +, ++, or - .
+ Scores underlined had CP identified on Warthin-Starry stain.
the 6- to 8-month follow-up in the three patients who
initially cleared the organism, there was normalization
of gastric mucosa in the two patients who remained
free of CP.
DISCUSSION
Chronic epigastric pain in the absence of ulcer disease
is a common clinical problem. Some of these patients
have endoscopic evidence of gastroduodenitis. but
many have a normal endoscopic appearance (8). Al-
though endoscopic and histologic inflammation corre-
late well in the duodenum, this is not true in the
stomach (1). Furthermore, the association between ab-
normal histology and symptoms remains unclear. Sev-
eral studies have shown poor symptomatic response
rates to standard ulcer therapy in nonulcer dyspepsia
(3, 4, 9, 10). One explanation for this result would be
that non-ulcer dyspepsia patients comprise a heteroge-
neous group. This series of 16 patients limited inclusion
by requiring the endoscopic diagnosis of erosions and
excluding patients taking aspirin or NSAIDs.
Over the past few years, gastric mucosal infection
with CP has been shown to have a strong correlation
with both peptic disease and histologic active gastritis.
In this study, we have shown that CP and its associated
histologic gastritis were present in 50% of the patients
with dyspepsia and endoscopically diagnosed gastric or
duodenal erosions. This 50% incidence is similar to the
50-70% incidence of CP infection reported in patients
with non-ulcer dyspepsia (11, 12). It has been suggested
that the higher incidence of CP infection in non-ulcer
dyspeptic patients than in asymptomatic controls (10-
20%) may point to a causal role of this organism for
these dyspeptic symptoms (13). However, this causal
role is thrown into question by the increased incidence
of CP infection with aging (14). The mean age ofour
patients with and without CP infection was 48.6 and
44.1 yr, respectively. A 50% incidence of CP infection
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in patients of this age group may not be significantly
different than an age-matched asymptomatic control
group (15). In our patients, dyspeptic symptoms per-
sisted for 4 yr regardless of whether they had gastritis
or CP, and improved on bismuth subsaHcylate and
metronidazole, also regardless of the presence of CP.
Other trials involving patients with non-ulcer dyspepsia
have reported improvement in symptoms with bismuth
therapy, compared wilh placebo, but have not studied
the symptom response to bismuth ofthe dyspeptic CP-
negative patients (5, 6). Perhaps bismuth compounds
are effective in relieving dyspeptic symptoms unrelated
to CP eradication. Of course, our study may be too
small to show a difference in symptom response be-
tween CP-negative and CP-positive patients.
Many of our histologic results agree with previous
investigators in finding: 7) the antrum was always in-
fected when CP was present and often had the highest
density of organisms, 2) CP was never found on normal
mucosa, 3) CP infection in the duodenum was only in
areas of gastric metaplasia, and 4) the presence of CP
correlates with activity in gastritis (16, 17). The disap-
pearance of polymorphonuclear cell infiltrate after CP
eradication without change in the underlying chronic
inflammatory infiltrate is unlike the report of Rauws et
al. (18). They showed improvement and even normal-
ization of gastric histology in CP-eradicated patients.
However, their gastritis scoring system was heavily
weighted in favor of polymorphonuclear cells and ero-
sions (8 out of 10 potential points) with only 2 out of
10 points for the chronic inflammatory infiltrate. Their
actual post CP treatment mean gastritis score was 1
(out of 2 potential points for chronic inflammation)
and did not return to 0 (normal) until 12 months post-
treatment. Therefore, our results of no change in
chronic inflammation post CP treatment are probably
consistent with theirs. Two ofthe three patients in our
study who cleared the organism did have normalization
of gastric mucosa at 6-8 months of follow-up.
A 4-yr follow-up of 10 of the original 16 patients
showed persistence of CP infection in the five patients
who had it originally, with no new appearance of CP
in the remaining five patients who were negative ini-
tially. Prior studies have not looked for persistence of
CP beyond 2 yr (19). It appears that CP causes chronic
infection with chronic histologic changes.
In conclusion, CP infection and its characteristic
histologic gastritis was present in 50% of patients with
endoscopically diagnosed erosive gastroduodenitis.
Dyspeptic symptoms and CP infection persisted over 4
yr of foilow-up. Treatment of both CP-positive and CP-
negative patients with bismuth subsaHcylate and met-
ronidazole improved symptoms, regardless of CP pres-
ence. This treatment result does not support a role for
CP infection or histologic gastritis in causing dyspeptic
symptoms, although our sample size was small. Large
trials of non-ulcer dyspepsia are needed to pursue this
issue further.
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